ThymopentinТимопентин
A synthetic pentapeptide corresponding to residues 32–36 of thymopoietin, Arg–Lys–Asp–Val–Tyr (RKDVY, TP-5). Human trials studied its effects in rheumatoid arthritis, atopic dermatitis and HIV.
What the studies found
Randomized study in people · 1990
Thymopentin versus placebo in moderate-to-severe atopic dermatitis
- Itch improved at week six
- 31/47 (66%) with thymopentin versus 18/45 (40%) with placebo (p=0.02).
- Itch improved by at least two grades
- 11/47 versus 2/45 (p=0.01).
- Affected body area
- Relative decline of 17% versus 4% (p=0.04). Overall severity also favored thymopentin (p=0.04).
Itch improved at week six · 31/47 (66%) with thymopentin versus 18/45 (40%) with placebo (p=0.02).
More reported outcomes
- Adverse experiences
- 14/48 versus 10/52 reported an adverse experience. The between-group difference was not statistically significant.
Study notes · methods, sources and limitations
Participants or model 100 participants randomized at two centers. Thymopentin n=48 and placebo n=52. Pruritus analysis included 47 and 45, respectively.
Design Double-blind comparison of 50 mg subcutaneous thymopentin daily for six weeks against placebo, followed by four weeks off treatment. Participants could continue topical corticosteroids and oral antihistamines.
Important limitations
- More placebo recipients withdrew, and the week-six pruritus analysis used available observations. Symptoms showed a trend toward rebound after injections stopped. The trial did not measure long-term control.
Journal of Allergy and Clinical Immunology 85(5), 927–933 · Publication record
Randomized study in people · 1994
Thymopentin as add-on treatment for severe atopic dermatitis
- Clinical improvement in severe eczema
- Significantly greater with thymopentin plus usual care than with placebo plus usual careWeek 12
- Reported drug-related adverse effects
- None reported in the abstract.
The 39-person double-blind trial reported significantly greater improvement at week 12 with thymopentin as an adjunct to usual eczema care.
Study notes · methods, sources and limitations
Participants or model 39 patients at least two years old with severe eczema involving at least 20% of the skin surface. Arm-level sample sizes are unavailable in the abstract.
Design Randomized double-blind placebo-controlled add-on trial with serial clinical assessments.
Important limitations
- The abstract gives no arm-level score changes or group sizes. The 1992 and 1993 conference presentations cited by the paper are earlier presentations of this work.
Journal of the American Academy of Dermatology. 1994;30(4):597–602. · Indexed abstract
Animal research · 2025
Thymopentin reduced tumor volume in immunocompetent mouse models
- Hepa1-6 tumor volume at day 24
- 341.10 ± 61.97 mm³ with thymopentin versus 666.01 ± 88.62 mm³ with saline (mean ± SEM, p<0.001). The treated mean was 48.8% lower.
- B16-F10 melanoma tumor volume at day 14
- 461.36 ± 93.85 mm³ versus 1,155.11 ± 232.42 mm³ (mean ± SEM, p<0.01) in the pretreatment model.
- Athymic LM3 model and cell assays
- Thymopentin failed to suppress tumor growth in the athymic model, and direct treatment did not reduce Hepa1-6 cell viability in vitro. Sorafenib inhibited growth in the athymic comparison.
Hepa1-6 tumor volume at day 24 · 341.10 ± 61.97 mm³ with thymopentin versus 666.01 ± 88.62 mm³ with saline (mean ± SEM, p<0.001). The treated mean was 48.8% lower.
More reported outcomes
- Adoptive T-cell transfer in melanoma-bearing mice
- 170.54 ± 30.81 mm³ with thymopentin plus OT-1 cells versus 368.64 ± 130.24 mm³ with OT-1 cells alone (p<0.05, five mice per group).
- Immune readouts
- The authors reported increased thymus mass and thymic T-cell counts and fewer PD-1/TIM-3 double-positive T cells in the tumor model.
Study notes · methods, sources and limitations
Participants or model Hepa1-6 liver tumor comparison used 11 mice per arm pooled from two experiments. The melanoma pretreatment comparison and athymic LM3 comparison used five mice per arm.
Design Thymopentin 20 mg/kg subcutaneously daily versus saline. Hepa1-6 treatment began on day 6 after inoculation and continued through day 24. Melanoma pretreatment began two weeks before inoculation and continued two weeks afterward. The athymic LM3 comparison also included sorafenib 30 mg/kg daily.
Important limitations
- The liver tumor comparisons used different cell lines in immunocompetent and athymic mice. The results support an immune mechanism in the tested models and leave clinical efficacy and durability unresolved. The melanoma experiment started before tumor implantation.
Biomedicines 13(10), 2494. · Original journal article
Thymopentin (TP-5) in cancer research
- Mouse liver tumors · 11 per group. At day 24, mean tumor volume was 341.10 mm³ with thymopentin versus 666.01 mm³ with saline (p<0.001). Thymopentin failed to inhibit tumor growth in the separate athymic model.
- Oncolytic adenovirus · mouse models. Depleting CD8 T cells or macrophages weakened the combination response.
- Chemotherapy-associated fever · 100 randomized. Fever occurred in 52% with thymopentin versus 64% with placebo, a statistically inconclusive difference.
- Colorectal cancer · 2026 systematic review. Two thymopentin comparisons reported a pooled 4.35-point difference in Karnofsky performance score. The review rated that estimate very low certainty and flagged similarities in the original reports.
Rheumatoid arthritis and HIV trials
Rheumatoid arthritis
- Veys, 1982 · 92 entrants. After six months, marked improvement was reported in 18% with 50 mg IV weekly, 6% with 1 mg IM weekly and 0% with saline. The IV arm was open and shared the saline group with the blinded IM comparison.
- Thrower, 1982 · 36 randomized. Pain scores fell by 7.67 points with thymopentin, 2.92 with levamisole and 5.00 with penicillamine. Three authors and the London center also contributed to the Veys report. Participant overlap is unresolved.
- Malaise, 1985 · 41 randomized. With 50 mg IV three times weekly for three weeks, joint tenderness, swelling and morning pain improved versus placebo. The 1984 interim report, Lancet paper and 1985 supplement describe the same 21 active and 20 placebo participants.
- Veys, 1984 · three comparisons. No significant clinical improvement was reported with subcutaneous regimens or with 100 mg/day IV. The abstract omits arm sizes.
HIV
- Conant, 1992 · 91 randomized. The 1990 conference abstract (L411) gives 47 thymopentin and 44 placebo participants at 50 mg subcutaneously three times weekly. In the journal report, 0 versus 2 initially asymptomatic participants developed symptoms by week 24 (p=0.12), and 2 per arm progressed to AIDS among those already symptomatic at entry.
- Goldstein, 1995 · 352 randomized. AIDS or death occurred in 2 versus 10 participants with more than six months of prior zidovudine and 4 versus 0 with six months or less. Merigan, 1996 reanalyzed the same trial. The 91- and 352-person reports used different enrollment criteria. Participant-level overlap across the two trials could not be verified.
- Clumeck, 1985 · three early pilots. The authors reported no clinical or immune improvement in five patients with AIDS. Overlap with the team’s 1983 report and 1984 report remains unresolved.
The arthritis literature includes short treatment courses and mixed results. The HIV trials predate modern combination antiretroviral therapy.
About Thymopentin
Names in this research collection
TP-5 · TP5 · RKDVY · Arg-Lys-Asp-Val-Tyr · Thymopoietin 32–36
Research background
Thymopentin (TP-5, RKDVY) is a synthetic five-amino-acid fragment of thymopoietin. A six-week eczema trial reported more itch improvement than placebo. A rheumatoid arthritis trial found short-term changes in clinical measures, and a 2025 dialysis cohort reported fewer infections among patients who received the peptide.
More study findings
Animal research · 2026
Thymopentin with oncolytic adenovirus in mouse tumor models
- H22 liver tumor response and rechallenge
- The authors observed tumor regression by day 35 in the combination group. Selected mice that had cleared H22 tumors resisted H22 rechallenge but developed 4T1 tumors after a separate challenge.
- Immune-cell dependence
- The combination increased cytotoxic CD8-positive T-cell and proinflammatory macrophage infiltration. Depletion of either cell population weakened the tumor response.
- Engineered adenovirus
- The thymopentin-expressing virus slowed tumor growth and prolonged survival in mouse experiments. The two viruses had similar replication and cell-killing behavior in the tested cell cultures.
H22 liver tumor response and rechallenge · The authors observed tumor regression by day 35 in the combination group. Selected mice that had cleared H22 tumors resisted H22 rechallenge but developed 4T1 tumors after a separate challenge.
Study notes · methods, sources and limitations
Participants or model 4T1 breast, CT26 colorectal and H22 liver tumor models in mice. Main comparisons used 6–8 mice per 4T1 arm, 9 per CT26 arm and 8 per H22 arm. The patient-derived breast tumor xenograft experiment used 5 mice per group.
Design Mouse arms compared saline, thymopentin, oncolytic adenovirus, and their combination. Adenovirus was given into the tumor at 2 × 10⁸ plaque-forming units every other day for three injections. Thymopentin was injected subcutaneously near the tumor daily. Additional experiments tested an engineered virus that expressed the peptide.
Important limitations
- All treatment experiments were preclinical, including experiments that used human tumor tissue grafted into mice. The main methods specify the injection frequency for free thymopentin without giving a mass dose. The rechallenge used selected mice that had already cleared tumors.
Communications Medicine 6, article 265 · Publication record
Letter or commentary · 2026
Myasthenia gravis reported after repeated thymopentin courses
- Clinical course
- Eyelid drooping first appeared after an October 2023 course. Chewing weakness and later neck weakness and dysphagia were reported after subsequent courses. Acetylcholine receptor antibody titer was 1:100.
- Myasthenia severity after treatment
- Quantitative Myasthenia Gravis score fell from 20 at admission to 10 at discharge and 3 at follow-up after thymopentin was stopped and myasthenia treatment was started.
Clinical course · Eyelid drooping first appeared after an October 2023 course. Chewing weakness and later neck weakness and dysphagia were reported after subsequent courses. Acetylcholine receptor antibody titer was 1:100.
Study notes · methods, sources and limitations
Participants or model One 75-year-old woman with persistent lymphopenia after treatment for triple-negative breast cancer.
Design Thymopentin was given at 10 mg every other day for 14 doses per course, with courses every six months beginning in 2019. The report does not specify the administration route.
Important limitations
- A single case supplies a temporal association. Prior cancer treatment and concurrent myasthenia therapy limit causal attribution, and incidence cannot be estimated.
Balkan Medical Journal 43, 291–293 · Publication record
Observational study · 2025
Thymopentin and infections in a peritoneal dialysis cohort
- Infection episodes
- 36 versus 49, or 0.73 versus 1.00 episodes per person-year. Adjusted hazard ratio for first infection 0.54 (95% CI 0.30–0.95, p=0.034).
- Peritonitis episodes
- 1 versus 8 (p=0.031).
- Severe infection and mortality
- 5 versus 10 severe infections (p=0.161). One patient died in each group.
Infection episodes · 36 versus 49, or 0.73 versus 1.00 episodes per person-year. Adjusted hazard ratio for first infection 0.54 (95% CI 0.30–0.95, p=0.034).
More reported outcomes
- IL-6 at week 12
- The full results show a smaller median increase (0.20 versus 1.10 pg/mL, p=0.036). There was no significant difference at weeks 24 or 48.
- Cell counts and adverse-event reporting
- No significant differences in CD4 counts or the CD4:CD8 ratio. The authors reported 12 versus 24 adverse events.
Study notes · methods, sources and limitations
Participants or model 100 peritoneal dialysis patients from a single center, 50 treated with thymopentin and 50 controls.
Design Retrospective cohort with 48 weeks of follow-up. The thymopentin protocol was 10 mg subcutaneously on each of the first five days, then three times weekly for 23 weeks.
Important limitations
- Treatment was selected in routine care. Differences in patients or care may have influenced the association. The study was small for severe infection and mortality. The article reports partial funding from the thymopentin manufacturer.
BMC Nephrology 26, article 538 · Publication record
- Compound class
- Thymopoietin-derived pentapeptide
- Research collection
- Peptide bioregulation · editorial grouping
- Institutions in linked studies
- See individual study records
- Source review
- Review dates and the material assessed are listed with each publication below.
Understanding the evidence
Human research
Placebo-controlled studies in atopic dermatitis, rheumatoid arthritis and HIV, plus a randomized COPD comparison and a retrospective dialysis cohort.
Study methods
Study notes provide tested regimens, comparators, group sizes and follow-up. Laboratory studies describe the peptide sequence, mouse immune-cell effects and isolated-plasma stability.
Independent replication
The outcomes differ by indication. Controlled rheumatoid arthritis studies include both short-term improvement and regimens with no significant benefit. HIV event counts differed across prior zidovudine groups. The related 1996 HIV analysis reused the 1995 trial cohort.
Source access
Original full texts and publisher or PubMed abstracts are linked per study.
Safety evidence
The rheumatoid arthritis trial reported one systemic allergic reaction. A 2026 case report described myasthenia gravis symptoms after repeated courses. The causal relationship remains uncertain.
Open a topic for the evidence assessment.
Patents and claimed inventions
These 2 grouped records distinguish claimed molecules, uses, formulations and related chemistry. Patent disclosure does not establish clinical benefit or approval.
Status is an indexed snapshot, not an official legal assessment. Search the patent collection and read the method →
Findings by study
Randomized study in people · 1994
Thymopentin as add-on treatment for severe atopic dermatitis
The 39-person double-blind trial reported significantly greater improvement at week 12 with thymopentin as an adjunct to usual eczema care.
Study notes and original source
Thymopentin as add-on treatment for severe atopic dermatitis
M. J. Stiller, J. L. Shupack, C. Kenny, L. Jondreau, D. E. Cohen, N. A. Soter · Journal of the American Academy of Dermatology. 1994;30(4):597–602.
The 39-person double-blind trial reported significantly greater improvement at week 12 with thymopentin as an adjunct to usual eczema care.
Results and tables
Reported findings and study design
Findings described in words
Randomized double-blind placebo-controlled add-on trial with serial clinical assessments.
Population or model 39 patients at least two years old with severe eczema involving at least 20% of the skin surface. Arm-level sample sizes are unavailable in the abstract.
Dose, route and schedule
Thymopentin 50 mg subcutaneously three times a week for 12 weeks or matching placebo. Both groups could use topical corticosteroids and oral antihistamines.
Protocol source ↗ · Original indexed abstract and publisher record, including the earlier presentation note.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Clinical improvement in severe eczema | Significantly greater with thymopentin plus usual care than with placebo plus usual care | Week 12 |
| Reported drug-related adverse effects | None reported in the abstract. |
Source for these results ↗ · Reviewed 2026-11-15
- Population / setting
- 39 patients at least two years old with severe eczema involving at least 20% of the skin surface. Arm-level sample sizes are unavailable in the abstract.
- Source reviewed
- Original indexed abstract and publisher record, including the earlier presentation note.
Study limitations
- The abstract gives no arm-level score changes or group sizes. The 1992 and 1993 conference presentations cited by the paper are earlier presentations of this work.
Reviewed 2026-11-15.
Comparison in people · 1982
Weekly thymopentin by intramuscular or intravenous injection in rheumatoid arthritis
Six-month global response · Marked improvement was reported in 18% on 50 mg IV, 6% on 1 mg IM and 0% on saline. The full global-response distribution favored IV treatment over saline (p=0.005) and over 1 mg IM (p=0.030).
Study notes and original source
Weekly thymopentin by intramuscular or intravenous injection in rheumatoid arthritis
Defined pentapeptide (RKDVY)
E. M. Veys, E. C. Huskisson, M. Rosenthal, T. L. Vischer, H. Mielants, P. A. Thrower, J. Scott, H. Ott, H. Scheijgrond, J. Symoens · Annals of the Rheumatic Diseases 41(5), 441–443
Six-month global response · Marked improvement was reported in 18% on 50 mg IV, 6% on 1 mg IM and 0% on saline. The full global-response distribution favored IV treatment over saline (p=0.005) and over 1 mg IM (p=0.030).
Results and tables
Reported findings and study design
Reported findings
Weekly injections for six months with assessments at baseline, three months and six months. The intramuscular arm and saline placebo were masked. The intravenous arm was open. Patients could continue analgesics and anti-inflammatory medication, with corticosteroids limited to the equivalent of 10 mg prednisolone per day.
Population or model 92 entrants across two comparisons. The double-blind study enrolled 21 patients on 1 mg intramuscular thymopentin and 20 on saline. A separate open study enrolled 51 patients on 50 mg intravenously and reused the 20 saline controls. At six months, 15, 16 and 44, respectively, were evaluable.
Dose, route and schedule
Weekly injections for six months with assessments at baseline, three months and six months. The intramuscular arm and saline placebo were masked. The intravenous arm was open. Patients could continue analgesics and anti-inflammatory medication, with corticosteroids limited to the equivalent of 10 mg prednisolone per day.
Protocol source ↗ · Original full text, pp. 441–443 and Tables 1–3.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Six-month global response | Marked improvement was reported in 18% on 50 mg IV, 6% on 1 mg IM and 0% on saline. The full global-response distribution favored IV treatment over saline (p=0.005) and over 1 mg IM (p=0.030). | |
| Intramuscular comparison | The 1 mg IM arm did not significantly differ from saline on the six-month global response. | |
| Safety | No adverse-event withdrawals. One fever was reported on 1 mg IM, and two rashes, one herpes zoster case and one diarrhea case on 50 mg IV. Attribution was uncertain. |
Six-month global response
| Outcome | Saline (n=20) | 1 mg IM (n=18) | 50 mg IV (n=44) |
|---|---|---|---|
| Marked improvement | 0% | 6% | 18% |
| Moderate improvement | 55% | 55% | 64% |
| Deterioration | 25% | 22% | 18% |
| Withdrawal for lack of effect | 20% | 17% | 0% |
The denominators in Table 3 include withdrawals for lack of effect. The two comparisons share one saline group.
Selected median clinical measures at baseline, month 3 and month 6
| Outcome | Saline | 1 mg IM | 50 mg IV |
|---|---|---|---|
| Ritchie tenderness index | 24.5 → 21 → 22.5 | 26 → 23 → 21 | 21 → 13 → 11 |
| Tender joints | 14 → 12.5 → 12.5 | 14 → 14 → 14 | 13 → 10 → 8 |
| Swollen joints | 8.5 → 7.5 → 8 | 7 → 6 → 6 | 8 → 6 → 6 |
| Pain, mm | 60.5 → 55.5 → 45 | 65 → 58 → 60 | 56 → 42 → 33 |
| Morning stiffness, min | 60 → 45 → 30 | 60 → 60 → 30 | 60 → 30 → 30 |
| Erythrocyte sedimentation rate, mm/h | 44.5 → 54 → 45 | 35 → 31.5 → 37 | 48 → 46 → 44 |
Table 2 tests within-arm changes. Sedimentation rate did not change significantly in any arm.
The 50 mg IV arm used the same controls as the intramuscular study and was unblinded. The Veys and Thrower groups shared London investigators, so any patient overlap between their 1982 reports remains unresolved.
Source for these results ↗ · Reviewed 2026-11-14
- Population / setting
- 92 entrants across two comparisons. The double-blind study enrolled 21 patients on 1 mg intramuscular thymopentin and 20 on saline. A separate open study enrolled 51 patients on 50 mg intravenously and reused the 20 saline controls. At six months, 15, 16 and 44, respectively, were evaluable.
- Source reviewed
- Original full text, pp. 441–443 and Tables 1–3.
Study limitations
- The 50 mg IV arm used the same controls as the intramuscular study and was unblinded. The Veys and Thrower groups shared London investigators, so any patient overlap between their 1982 reports remains unresolved.
Reviewed 2026-11-14.
Randomized study in people · 1982
Thymopentin compared with levamisole and penicillamine in rheumatoid arthritis
Six-month pain score reduction · 7.67 points with thymopentin, 2.92 with levamisole and 5.00 with penicillamine. Thymopentin differed from levamisole (p<0.05).
Study notes and original source
Thymopentin compared with levamisole and penicillamine in rheumatoid arthritis
Defined pentapeptide (RKDVY)
P. A. Thrower, D. V. Doyle, J. Scott, E. C. Huskisson · Rheumatology and Rehabilitation 21(2), 72–77
Six-month pain score reduction · 7.67 points with thymopentin, 2.92 with levamisole and 5.00 with penicillamine. Thymopentin differed from levamisole (p<0.05).
Results and tables
Reported findings and study design
Reported findings
Randomized six-month comparison of thymopentin 50 mg IV once weekly, levamisole 150 mg orally once weekly, or penicillamine 250–750 mg orally daily. The clinical assessor was masked and patients knew their treatment. Existing anti-inflammatory therapy continued. Eleven thymopentin recipients subsequently crossed to levamisole.
Population or model 36 adults with active rheumatoid arthritis at St Bartholomew’s Hospital in London, 12 assigned to each of three treatment groups.
Dose, route and schedule
Randomized six-month comparison of thymopentin 50 mg IV once weekly, levamisole 150 mg orally once weekly, or penicillamine 250–750 mg orally daily. The clinical assessor was masked and patients knew their treatment. Existing anti-inflammatory therapy continued. Eleven thymopentin recipients subsequently crossed to levamisole.
Protocol source ↗ · Original full-text scan, methods and Tables II–V.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Six-month pain score reduction | 7.67 points with thymopentin, 2.92 with levamisole and 5.00 with penicillamine. Thymopentin differed from levamisole (p<0.05). | |
| Other clinical outcomes | No other clinical comparison with levamisole or penicillamine reached statistical significance. Thymopentin’s mean ESR fell by 9.75 mm/h (0.05<p<0.10). | |
| Adverse events in the thymopentin arm | Two rashes and one mild herpes zoster case. One rash worsened after successive injections and resolved after treatment stopped. |
Six-month mean reductions, with standard errors
| Measure | Thymopentin (n=12) | Levamisole (n=12) | Penicillamine (n=12) |
|---|---|---|---|
| Pain score | 7.67 ± 1.38 | 2.92 ± 1.68 | 5.00 ± 1.38 |
| Morning stiffness, min | 68.75 ± 20.95 | 28.75 ± 15.19 | 29.25 ± 11.85 |
| Articular index | 8.00 ± 1.72 | 5.25 ± 1.51 | 4.58 ± 0.80 |
With 12 per arm and patients aware of assignment, the pain result is vulnerable to expectation effects. The study did not establish equivalence to penicillamine. Three authors and the London center also appear in Veys’s 1982 paper, so participant overlap cannot be ruled out.
Source for these results ↗ · Reviewed 2026-11-14
- Population / setting
- 36 adults with active rheumatoid arthritis at St Bartholomew’s Hospital in London, 12 assigned to each of three treatment groups.
- Source reviewed
- Original full-text scan, methods and Tables II–V.
Study limitations
- With 12 per arm and patients aware of assignment, the pain result is vulnerable to expectation effects. The study did not establish equivalence to penicillamine. Three authors and the London center also appear in Veys’s 1982 paper, so participant overlap cannot be ruled out.
Reviewed 2026-11-14.
Comparison in people · 1984
Three rheumatoid arthritis comparisons found no significant improvement
Clinical response across the three studies · None of the three studies found statistically significant clinical improvement. Most patients failed to improve or dropped out for lack of effect.
Study notes and original source
Three rheumatoid arthritis comparisons found no significant improvement
Defined pentapeptide (RKDVY)
E. M. Veys, H. Mielants, G. Verbruggen, T. Spiro, E. Newdeck, D. Power, G. Goldstein · Journal of Rheumatology 11(4), 462–466
Clinical response across the three studies · None of the three studies found statistically significant clinical improvement. Most patients failed to improve or dropped out for lack of effect.
Results and tables
Reported findings and study design
Reported findings
A six-month double-blind placebo comparison of three subcutaneous doses, a long-term open subcutaneous study, and a three-week double-blind study of 100 mg/day intravenously. The abstract does not list the subcutaneous dose levels.
Population or model Three rheumatoid arthritis studies. The indexed abstract omits enrollment and arm sizes.
Dose, route and schedule
A six-month double-blind placebo comparison of three subcutaneous doses, a long-term open subcutaneous study, and a three-week double-blind study of 100 mg/day intravenously. The abstract does not list the subcutaneous dose levels.
Protocol source ↗ · Original indexed abstract of a three-study report.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Clinical response across the three studies | None of the three studies found statistically significant clinical improvement. Most patients failed to improve or dropped out for lack of effect. | |
| Reported safety | The authors reported no serious side effects. |
The available abstract gives no arm-level outcome values or counts. Its protocols differ from the weekly injection comparisons in Veys’s 1982 paper, and no cross-trial participant total is available.
Source for these results ↗ · Reviewed 2026-11-14
- Population / setting
- Three rheumatoid arthritis studies. The indexed abstract omits enrollment and arm sizes.
- Source reviewed
- Original indexed abstract of a three-study report.
Study limitations
- The available abstract gives no arm-level outcome values or counts. Its protocols differ from the weekly injection comparisons in Veys’s 1982 paper, and no cross-trial participant total is available.
Reviewed 2026-11-14.
Randomized study in people · 1985
Slow-injection thymopentin versus placebo in active rheumatoid arthritis
Between-group clinical findings · At week three, thymopentin performed better than placebo on joint tenderness, swelling, pain on awakening and overall disease activity.
Study notes and original source
Slow-injection thymopentin versus placebo in active rheumatoid arthritis
Defined pentapeptide (RKDVY)
M. G. Malaise, C. Hauwaert, P. Franchimont, B. Danneskiold-Samsoe, R. Bach-Andersen, D. Gross, H. Gerber, H. Gerschpacher, H. Stocker, K. Bolla · The Lancet 1(8433), 832–836
Between-group clinical findings · At week three, thymopentin performed better than placebo on joint tenderness, swelling, pain on awakening and overall disease activity.
Results and tables
Reported findings and study design
Reported findings
Double-blind comparison of 50 mg IV in divided pushes over 10 minutes, three times weekly for three weeks. The control arm received placebo in the same way. Follow-up continued four weeks after treatment.
Population or model 41 randomized participants with active rheumatoid arthritis, 21 thymopentin and 20 placebo.
Dose, route and schedule
Double-blind comparison of 50 mg IV in divided pushes over 10 minutes, three times weekly for three weeks. The control arm received placebo in the same way. Follow-up continued four weeks after treatment.
Protocol source ↗ · Original indexed abstract and Lancet opening page. The full archive copy requires access.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Between-group clinical findings | At week three, thymopentin performed better than placebo on joint tenderness, swelling, pain on awakening and overall disease activity. | |
| Other measures and follow-up | Left-hand grip did not improve on thymopentin. Placebo improved morning stiffness within the group. Some improvement persisted at four weeks off treatment, with a trend toward relapse. | |
| Laboratory markers and safety | No significant changes in tested laboratory measures. Both arms reported minor side effects. |
Absolute group means and adverse-event counts are unavailable in the accessible pages. The 1984 interim and 1985 supplement reports match the same 21/20 arms, dosing and endpoints. Together the three reports contribute one 41-person cohort.
Source for these results ↗ · Reviewed 2026-11-14
- Population / setting
- 41 randomized participants with active rheumatoid arthritis, 21 thymopentin and 20 placebo.
- Source reviewed
- Original indexed abstract and Lancet opening page. The full archive copy requires access.
Study limitations
- Absolute group means and adverse-event counts are unavailable in the accessible pages. The 1984 interim and 1985 supplement reports match the same 21/20 arms, dosing and endpoints. Together the three reports contribute one 41-person cohort.
Reviewed 2026-11-14.
Randomized study in people · 1989
UK multicenter comparison of slow IV thymopentin in rheumatoid arthritis
Joint tenderness and swelling · The Ritchie tenderness index and swollen-joint score improved significantly versus placebo. The abstract gives no numeric changes.
Study notes and original source
UK multicenter comparison of slow IV thymopentin in rheumatoid arthritis
Defined pentapeptide (RKDVY)
B. K. Kantharia, N. J. Goulding, N. D. Hall, J. Davies, P. J. Maddison, P. A. Bacon, M. Farr, J. A. Wojtulewski, K. M. Englehart, S. P. Liyanage, N. L. Cox · British Journal of Rheumatology 28(2), 118–123
Joint tenderness and swelling · The Ritchie tenderness index and swollen-joint score improved significantly versus placebo. The abstract gives no numeric changes.
Results and tables
Reported findings and study design
Reported findings
Randomized comparison of slow IV thymopentin 50 mg or placebo three times weekly for three weeks. Follow-up ran to week seven.
Population or model 76 participants with rheumatoid arthritis across UK centers. Arm sizes are unavailable in the abstract.
Dose, route and schedule
Randomized comparison of slow IV thymopentin 50 mg or placebo three times weekly for three weeks. Follow-up ran to week seven.
Protocol source ↗ · Original publisher abstract and affiliations.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Joint tenderness and swelling | The Ritchie tenderness index and swollen-joint score improved significantly versus placebo. The abstract gives no numeric changes. | |
| Laboratory results and tolerability | Routine laboratory measures did not change. Skin-test responses to common recall antigens increased. Toxicity was described as minimal, without event counts. |
The UK affiliations distinguish this report from the Malaise multicenter report and the Lemmel German report. The accessible abstract does not specify masking or assess lasting structural outcomes.
Source for these results ↗ · Reviewed 2026-11-14
- Population / setting
- 76 participants with rheumatoid arthritis across UK centers. Arm sizes are unavailable in the abstract.
- Source reviewed
- Original publisher abstract and affiliations.
Study limitations
- The UK affiliations distinguish this report from the Malaise multicenter report and the Lemmel German report. The accessible abstract does not specify masking or assess lasting structural outcomes.
Reviewed 2026-11-14.
Study involving people · 1991
Eight weeks of intravenous thymopentin in active rheumatoid arthritis
Study-defined response at six to eight weeks · 11/20 responded. Two improved in functional class and nine showed mild symptom improvement. Seven were unchanged and two worsened. No remission was reported.
Study notes and original source
Eight weeks of intravenous thymopentin in active rheumatoid arthritis
Defined pentapeptide (RKDVY)
D. H. Yoo, S. C. Bae, C. H. Park, S. Y. Kim · Korean Journal of Internal Medicine (Korean-language edition) 41(4), 518–524
Study-defined response at six to eight weeks · 11/20 responded. Two improved in functional class and nine showed mild symptom improvement. Seven were unchanged and two worsened. No remission was reported.
Results and tables
Reported findings and study design
Reported findings
50 mg thymopentin mixed with 10 mL saline, infused IV over 10 minutes three times weekly for eight weeks. Existing NSAIDs continued at unchanged doses. Corticosteroids and disease-modifying antirheumatic drugs were withheld during treatment.
Population or model 20 people with active rheumatoid arthritis at Hanyang University, Seoul. There was no comparison group.
Dose, route and schedule
50 mg thymopentin mixed with 10 mL saline, infused IV over 10 minutes three times weekly for eight weeks. Existing NSAIDs continued at unchanged doses. Corticosteroids and disease-modifying antirheumatic drugs were withheld during treatment.
Protocol source ↗ · Original Korean full text, including Tables 1, 3 and 5.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Study-defined response at six to eight weeks | 11/20 responded. Two improved in functional class and nine showed mild symptom improvement. Seven were unchanged and two worsened. No remission was reported. | |
| Follow-up and safety | Only three still showed improvement six weeks after treatment ended. Three participants had transient adverse effects, and none stopped treatment because of them. |
The response rule was specific to the study, and changes from baseline came from an uncontrolled single-center series.
Source for these results ↗ · Reviewed 2026-11-14
- Population / setting
- 20 people with active rheumatoid arthritis at Hanyang University, Seoul. There was no comparison group.
- Source reviewed
- Original Korean full text, including Tables 1, 3 and 5.
Study limitations
- The response rule was specific to the study, and changes from baseline came from an uncontrolled single-center series.
Reviewed 2026-11-14.
Study involving people · 1985
Early thymopentin pilot series in AIDS and symptomatic HIV
Advanced AIDS, 50 mg slow IV (n=5) · The investigators reported no immunological or clinical improvement.
Study notes and original source
Early thymopentin pilot series in AIDS and symptomatic HIV
Defined pentapeptide (RKDVY)
N. Clumeck, S. Cran, P. Van de Perre, F. Mascart-Lemone, J. Duchateau, K. Bolla · Survey of Immunologic Research 4(Suppl 1), 58–62
Advanced AIDS, 50 mg slow IV (n=5) · The investigators reported no immunological or clinical improvement.
Results and tables
Reported findings and study design
Reported findings
Five with AIDS received 50 mg by slow IV infusion three times weekly. Six with earlier symptomatic disease received 50 mg IV three times weekly as a bolus for one month and then as a slow infusion for one month. A further five received 15 mg subcutaneously three times weekly.
Population or model Three uncontrolled groups of 5, 6 and 5 described by the Belgian team.
Dose, route and schedule
Five with AIDS received 50 mg by slow IV infusion three times weekly. Six with earlier symptomatic disease received 50 mg IV three times weekly as a bolus for one month and then as a slow infusion for one month. A further five received 15 mg subcutaneously three times weekly.
Protocol source ↗ · Original indexed abstract of three pilot series.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Advanced AIDS, 50 mg slow IV (n=5) | The investigators reported no immunological or clinical improvement. | |
| Earlier symptomatic disease, IV (n=6) | Immune measures and clinical status improved during the slow-infusion period. The response reportedly persisted for a mean of eight months. The abstract does not give individual responder counts. | |
| Earlier symptomatic disease, 15 mg subcutaneous (n=5) | 1/5 had reported clinical and immunological improvement. |
These were uncontrolled pilots with sequential treatment in the six-person group. The same team published earlier reports in 1983 and 1984. Participant overlap with those reports is unresolved, so their sample sizes cannot be added.
Source for these results ↗ · Reviewed 2026-11-14
- Population / setting
- Three uncontrolled groups of 5, 6 and 5 described by the Belgian team.
- Source reviewed
- Original indexed abstract of three pilot series.
Study limitations
- These were uncontrolled pilots with sequential treatment in the six-person group. The same team published earlier reports in 1983 and 1984. Participant overlap with those reports is unresolved, so their sample sizes cannot be added.
Reviewed 2026-11-14.
Randomized study in people · 1992
Thymopentin versus placebo in a 91-person HIV trial
Progression to symptoms among asymptomatic participants · 0 versus 2 through week 24 (placebo Kaplan–Meier estimate 9.1%, p=0.12). The journal abstract reports one additional placebo event in the 52-week subset.
Study notes and original source
Thymopentin versus placebo in a 91-person HIV trial
Defined pentapeptide (RKDVY)
M. A. Conant, L. H. Calabrese, S. E. Thompson, B. J. Poiesz, S. Rasheed, R. L. Hirsch, L. A. Meyerson, A. B. Kremer, C. C. Wang, G. Goldstein · AIDS 6(11), 1335–1339
Progression to symptoms among asymptomatic participants · 0 versus 2 through week 24 (placebo Kaplan–Meier estimate 9.1%, p=0.12). The journal abstract reports one additional placebo event in the 52-week subset.
Results and tables
Reported findings and study design
Reported findings
Randomized, double-blind comparison of 50 mg thymopentin or placebo subcutaneously three times weekly. Randomization was stratified by baseline HIV symptoms.
Population or model 91 enrolled across three sites. The conference report gives 47 thymopentin and 44 placebo. The journal report gives 52 asymptomatic and 39 symptomatic participants, with 45 assigned to 24 weeks and 46 to 52 weeks of blinded evaluation.
Dose, route and schedule
Randomized, double-blind comparison of 50 mg thymopentin or placebo subcutaneously three times weekly. Randomization was stratified by baseline HIV symptoms.
Protocol source ↗ · Original journal abstract and the investigators’ 1990 conference abstract L411, p. 148.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Progression to symptoms among asymptomatic participants | 0 versus 2 through week 24 (placebo Kaplan–Meier estimate 9.1%, p=0.12). The journal abstract reports one additional placebo event in the 52-week subset. | |
| CD4 measures among asymptomatic participants | The area under the percent-CD4 curve favored thymopentin (p=0.03), as did time to a 20% rise in percent CD4 (p=0.04) through week 24. | |
| Progression to AIDS among symptomatic participants | The journal report gives two events in each arm. It reports no serious adverse effects attributed to thymopentin. |
The matching 1990 conference report supplies arm sizes and gives a more favorable early combined progression count. The later journal report gives different outcomes by symptom group. Few clinical events and subgroup analyses limit the interpretation.
Source for these results ↗ · Reviewed 2026-11-14
- Population / setting
- 91 enrolled across three sites. The conference report gives 47 thymopentin and 44 placebo. The journal report gives 52 asymptomatic and 39 symptomatic participants, with 45 assigned to 24 weeks and 46 to 52 weeks of blinded evaluation.
- Source reviewed
- Original journal abstract and the investigators’ 1990 conference abstract L411, p. 148.
Study limitations
- The matching 1990 conference report supplies arm sizes and gives a more favorable early combined progression count. The later journal report gives different outcomes by symptom group. Few clinical events and subgroup analyses limit the interpretation.
Reviewed 2026-11-14.
Observational study · 1996
Viral load and resistance markers in the 352-person zidovudine trial
Progression to AIDS-related complex, AIDS or death · Across both randomized trial strata, the reanalysis reported a relative hazard of 3.0 favoring thymopentin (p=0.015).
Study notes and original source
Viral load and resistance markers in the 352-person zidovudine trial
Defined pentapeptide (RKDVY)
T. C. Merigan, R. L. Hirsch, A. C. Fisher, L. A. Meyerson, G. Goldstein, M. A. Winters · AIDS 10(2), 159–165
Progression to AIDS-related complex, AIDS or death · Across both randomized trial strata, the reanalysis reported a relative hazard of 3.0 favoring thymopentin (p=0.015).
Results and tables
Reported findings and study design
Reported findings
Post hoc analysis of baseline CD4 count, viral load, zidovudine resistance at codon 215 and immune-complex-dissociated p24. The parent trial gave 50 mg thymopentin or placebo subcutaneously three times weekly for up to 48 weeks. Most markers were assayed in stored samples after trial completion.
Population or model The same 352 zidovudine-treated participants enrolled in the 1995 placebo-controlled trial.
Dose, route and schedule
Post hoc analysis of baseline CD4 count, viral load, zidovudine resistance at codon 215 and immune-complex-dissociated p24. The parent trial gave 50 mg thymopentin or placebo subcutaneously three times weekly for up to 48 weeks. Most markers were assayed in stored samples after trial completion.
Protocol source ↗ · Original indexed abstract of the retrospective analysis.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Progression to AIDS-related complex, AIDS or death | Across both randomized trial strata, the reanalysis reported a relative hazard of 3.0 favoring thymopentin (p=0.015). | |
| Baseline factors associated with progression | Codon 215 mutation, viral load ≥20,000 RNA copies/mL and CD4 below 350 cells/µL were associated with progression. Baseline p24 ≥30 pg/mL was inconclusive (p=0.52). |
The treatment analyses were retrospective and used the original randomized cohort. Biomarker subgroup results require independent confirmation. The trial predates current combination HIV therapy.
Source for these results ↗ · Reviewed 2026-11-14
- Population / setting
- The same 352 zidovudine-treated participants enrolled in the 1995 placebo-controlled trial.
- Source reviewed
- Original indexed abstract of the retrospective analysis.
Study limitations
- The treatment analyses were retrospective and used the original randomized cohort. Biomarker subgroup results require independent confirmation. The trial predates current combination HIV therapy.
Reviewed 2026-11-14.
Animal research · 2026
Thymopentin with oncolytic adenovirus in mouse tumor models
H22 liver tumor response and rechallenge · The authors observed tumor regression by day 35 in the combination group. Selected mice that had cleared H22 tumors resisted H22 rechallenge but developed 4T1 tumors after a separate challenge.
Study notes and original source
Thymopentin with oncolytic adenovirus in mouse tumor models
Defined pentapeptide (RKDVY)
L. Kong, K. Liu, Y. Liu, H. Cui, P. Wang, J. Qiu, Q. Xin, D. Zhou, W. Liu, F. Zhao, J. Wu, X. Gu, J. Wu, C. Jiang · Communications Medicine 6, article 265
H22 liver tumor response and rechallenge · The authors observed tumor regression by day 35 in the combination group. Selected mice that had cleared H22 tumors resisted H22 rechallenge but developed 4T1 tumors after a separate challenge.
Results and tables
Reported findings and study design
Reported findings
Mouse arms compared saline, thymopentin, oncolytic adenovirus, and their combination. Adenovirus was given into the tumor at 2 × 10⁸ plaque-forming units every other day for three injections. Thymopentin was injected subcutaneously near the tumor daily. Additional experiments tested an engineered virus that expressed the peptide.
Population or model 4T1 breast, CT26 colorectal and H22 liver tumor models in mice. Main comparisons used 6–8 mice per 4T1 arm, 9 per CT26 arm and 8 per H22 arm. The patient-derived breast tumor xenograft experiment used 5 mice per group.
Dose, route and schedule
Mouse arms compared saline, thymopentin, oncolytic adenovirus, and their combination. Adenovirus was given into the tumor at 2 × 10⁸ plaque-forming units every other day for three injections. Thymopentin was injected subcutaneously near the tumor daily. Additional experiments tested an engineered virus that expressed the peptide.
Protocol source ↗ · Original full text, including study methods and Figures 1–5 and 7.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| H22 liver tumor response and rechallenge | The authors observed tumor regression by day 35 in the combination group. Selected mice that had cleared H22 tumors resisted H22 rechallenge but developed 4T1 tumors after a separate challenge. | |
| Immune-cell dependence | The combination increased cytotoxic CD8-positive T-cell and proinflammatory macrophage infiltration. Depletion of either cell population weakened the tumor response. | |
| Engineered adenovirus | The thymopentin-expressing virus slowed tumor growth and prolonged survival in mouse experiments. The two viruses had similar replication and cell-killing behavior in the tested cell cultures. |
All treatment experiments were preclinical, including experiments that used human tumor tissue grafted into mice. The main methods specify the injection frequency for free thymopentin without giving a mass dose. The rechallenge used selected mice that had already cleared tumors.
Source for these results ↗ · Reviewed 2026-11-14
- Population / setting
- 4T1 breast, CT26 colorectal and H22 liver tumor models in mice. Main comparisons used 6–8 mice per 4T1 arm, 9 per CT26 arm and 8 per H22 arm. The patient-derived breast tumor xenograft experiment used 5 mice per group.
- Source reviewed
- Original full text, including study methods and Figures 1–5 and 7.
Study limitations
- All treatment experiments were preclinical, including experiments that used human tumor tissue grafted into mice. The main methods specify the injection frequency for free thymopentin without giving a mass dose. The rechallenge used selected mice that had already cleared tumors.
Reviewed 2026-11-14.
Letter or commentary · 2026
Myasthenia gravis reported after repeated thymopentin courses
Clinical course · Eyelid drooping first appeared after an October 2023 course. Chewing weakness and later neck weakness and dysphagia were reported after subsequent courses. Acetylcholine receptor antibody titer was 1:100.
Study notes and original source
Myasthenia gravis reported after repeated thymopentin courses
Defined pentapeptide (RKDVY)
N. Zhao, L. Yang, T. Li · Balkan Medical Journal 43, 291–293
Clinical course · Eyelid drooping first appeared after an October 2023 course. Chewing weakness and later neck weakness and dysphagia were reported after subsequent courses. Acetylcholine receptor antibody titer was 1:100.
Results and tables
Reported findings and study design
Reported findings
Thymopentin was given at 10 mg every other day for 14 doses per course, with courses every six months beginning in 2019. The report does not specify the administration route.
Population or model One 75-year-old woman with persistent lymphopenia after treatment for triple-negative breast cancer.
Dose, route and schedule
Thymopentin was given at 10 mg every other day for 14 doses per course, with courses every six months beginning in 2019. The report does not specify the administration route.
Protocol source ↗ · Original case report, including clinical timeline and electrophysiology table.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Clinical course | Eyelid drooping first appeared after an October 2023 course. Chewing weakness and later neck weakness and dysphagia were reported after subsequent courses. Acetylcholine receptor antibody titer was 1:100. | |
| Myasthenia severity after treatment | Quantitative Myasthenia Gravis score fell from 20 at admission to 10 at discharge and 3 at follow-up after thymopentin was stopped and myasthenia treatment was started. |
A single case supplies a temporal association. Prior cancer treatment and concurrent myasthenia therapy limit causal attribution, and incidence cannot be estimated.
Source for these results ↗ · Reviewed 2026-11-14
- Population / setting
- One 75-year-old woman with persistent lymphopenia after treatment for triple-negative breast cancer.
- Source reviewed
- Original case report, including clinical timeline and electrophysiology table.
Study limitations
- A single case supplies a temporal association. Prior cancer treatment and concurrent myasthenia therapy limit causal attribution, and incidence cannot be estimated.
Reviewed 2026-11-14.
Randomized study in people · 1990
Thymopentin versus placebo in moderate-to-severe atopic dermatitis
Itch improved at week six · 31/47 (66%) with thymopentin versus 18/45 (40%) with placebo (p=0.02).
Study notes and original source
Thymopentin versus placebo in moderate-to-severe atopic dermatitis
Defined pentapeptide (RKDVY)
D. Y. Leung, R. L. Hirsch, L. Schneider, C. Moody, R. Takaoka, S. H. Li, L. A. Meyerson, S. G. Mariam, G. Goldstein, J. M. Hanifin · Journal of Allergy and Clinical Immunology 85(5), 927–933
Itch improved at week six · 31/47 (66%) with thymopentin versus 18/45 (40%) with placebo (p=0.02).
Results and tables
Reported findings and study design
Reported findings
Double-blind comparison of 50 mg subcutaneous thymopentin daily for six weeks against placebo, followed by four weeks off treatment. Participants could continue topical corticosteroids and oral antihistamines.
Population or model 100 participants randomized at two centers. Thymopentin n=48 and placebo n=52. Pruritus analysis included 47 and 45, respectively.
Dose, route and schedule
Double-blind comparison of 50 mg subcutaneous thymopentin daily for six weeks against placebo, followed by four weeks off treatment. Participants could continue topical corticosteroids and oral antihistamines.
Protocol source ↗ · Original report, including the pruritus and safety results.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Itch improved at week six | 31/47 (66%) with thymopentin versus 18/45 (40%) with placebo (p=0.02). | |
| Itch improved by at least two grades | 11/47 versus 2/45 (p=0.01). | |
| Affected body area | Relative decline of 17% versus 4% (p=0.04). Overall severity also favored thymopentin (p=0.04). | |
| Adverse experiences | 14/48 versus 10/52 reported an adverse experience. The between-group difference was not statistically significant. |
Six-week pruritus results
| Outcome | Thymopentin (n=47) | Placebo (n=45) | Reported p |
|---|---|---|---|
| Any improvement | 31 (66%) | 18 (40%) | 0.02 |
| Improvement of at least two grades | 11 | 2 | 0.01 |
| Worsening | 4 | 3 | — |
More placebo recipients withdrew, and the week-six pruritus analysis used available observations. Symptoms showed a trend toward rebound after injections stopped. The trial did not measure long-term control.
Source for these results ↗ · Reviewed 2026-11-14
- Population / setting
- 100 participants randomized at two centers. Thymopentin n=48 and placebo n=52. Pruritus analysis included 47 and 45, respectively.
- Source reviewed
- Original report, including the pruritus and safety results.
Study limitations
- More placebo recipients withdrew, and the week-six pruritus analysis used available observations. Symptoms showed a trend toward rebound after injections stopped. The trial did not measure long-term control.
Reviewed 2026-11-14.
Randomized study in people · 1988
Thymopentin versus placebo in a multicenter rheumatoid arthritis trial
Steinbrocker functional class · Improved in 7/51 thymopentin recipients versus 0/56 placebo recipients.
Study notes and original source
Thymopentin versus placebo in a multicenter rheumatoid arthritis trial
Defined pentapeptide (RKDVY)
E. M. Lemmel, G. L. Bach, W. Bolten, D. Brackertz, Z. Fahmy, H. Mattern, I. Stroehmann, A. Wittenborg · Deutsche Medizinische Wochenschrift 113(5), 172–176
Steinbrocker functional class · Improved in 7/51 thymopentin recipients versus 0/56 placebo recipients.
Results and tables
Reported findings and study design
Reported findings
Double-blind, multicenter placebo comparison. Thymopentin 50 mg by intravenous injection over 10 minutes three times per week for three weeks, with four additional weeks of observation.
Population or model 119 randomized participants with rheumatoid arthritis. The analysis included 107 participants (51 thymopentin and 56 placebo).
Dose, route and schedule
Double-blind, multicenter placebo comparison. Thymopentin 50 mg by intravenous injection over 10 minutes three times per week for three weeks, with four additional weeks of observation.
Protocol source ↗ · English abstract of the original German article. A full copy was unavailable for extraction.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Steinbrocker functional class | Improved in 7/51 thymopentin recipients versus 0/56 placebo recipients. | |
| Clinical and laboratory measures | Five of nine clinical criteria showed improvement at week three. The authors report a higher frequency of improvement of at least 40% in individual clinical criteria, without giving the response counts. Effects diminished over the next four weeks and laboratory measures did not change. | |
| Safety | One systemic allergic reaction was reported. |
Twelve randomized participants were omitted from the analysis. The abstract provides limited per-endpoint data, and the brief follow-up leaves effects on lasting disability and joint damage unresolved.
Source for these results ↗ · Reviewed 2026-11-14
- Population / setting
- 119 randomized participants with rheumatoid arthritis. The analysis included 107 participants (51 thymopentin and 56 placebo).
- Source reviewed
- English abstract of the original German article. A full copy was unavailable for extraction.
Study limitations
- Twelve randomized participants were omitted from the analysis. The abstract provides limited per-endpoint data, and the brief follow-up leaves effects on lasting disability and joint damage unresolved.
Reviewed 2026-11-14.
Randomized study in people · 1995
Thymopentin added to zidovudine in a randomized HIV trial
AIDS or death after more than six months of prior AZT · 2 events with thymopentin versus 10 with placebo (p=0.024). The authors report a relative risk of 4.9 in the placebo-to-thymopentin direction (95% CI 1.1–22.2).
Study notes and original source
Thymopentin added to zidovudine in a randomized HIV trial
Defined pentapeptide (RKDVY)
G. Goldstein, M. A. Conant, G. Beall, H. A. Grossman, J. E. Galpin, G. Blick, L. H. Calabrese, R. L. Hirsch, A. Fisher, P. Stampone · Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 8(3), 279–288
AIDS or death after more than six months of prior AZT · 2 events with thymopentin versus 10 with placebo (p=0.024). The authors report a relative risk of 4.9 in the placebo-to-thymopentin direction (95% CI 1.1–22.2).
Results and tables
Reported findings and study design
Reported findings
Double-blind multicenter comparison of thymopentin 50 mg subcutaneously three times per week against placebo for up to 48 weeks. All participants continued zidovudine (AZT). The investigators analyzed outcomes by intention to treat and reported a statistically significant treatment-by-stratum interaction.
Population or model 352 asymptomatic participants with 200–500 CD4 cells/µL randomized. Prior zidovudine exposure exceeded six months in 235 participants (mean 16 months in this group) and was six months or less in 117.
Dose, route and schedule
Double-blind multicenter comparison of thymopentin 50 mg subcutaneously three times per week against placebo for up to 48 weeks. All participants continued zidovudine (AZT). The investigators analyzed outcomes by intention to treat and reported a statistically significant treatment-by-stratum interaction.
Protocol source ↗ · Original indexed abstract. It reports event counts and total strata sizes.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| AIDS or death after more than six months of prior AZT | 2 events with thymopentin versus 10 with placebo (p=0.024). The authors report a relative risk of 4.9 in the placebo-to-thymopentin direction (95% CI 1.1–22.2). | |
| AIDS or death after six months or less of prior AZT | 4 events with thymopentin versus 0 with placebo (p=0.11). | |
| Laboratory measures and tolerability | No between-group differences in CD4 counts, HIV p24 antigen or reported clinical and laboratory adverse experiences. |
Reported event counts by prior zidovudine exposure
| Prior zidovudine | Outcome | Thymopentin events | Placebo events | Reported p | Reported relative risk (95% CI) |
|---|---|---|---|---|---|
| More than 6 months (235 total) | AIDS or death | 2 | 10 | 0.024 | 4.9 (1.1–22.2) |
| More than 6 months (235 total) | AIDS-related complex, AIDS or death | 3 | 18 | 0.001 | 5.9 (1.7–20.0) |
| 6 months or less (117 total) | AIDS or death | 4 | 0 | 0.11 | — |
| 6 months or less (117 total) | AIDS-related complex, AIDS or death | 4 | 2 | 0.79 | — |
Relative risks shown are placebo versus thymopentin. Per-arm denominators within each stratum are unavailable in the abstract.
The clinical finding varied across prior-treatment groups and involved few events. The 1996 biomarker paper reanalyzed these same 352 participants. The trial predates modern combination antiretroviral treatment.
Source for these results ↗ · Reviewed 2026-11-14
- Population / setting
- 352 asymptomatic participants with 200–500 CD4 cells/µL randomized. Prior zidovudine exposure exceeded six months in 235 participants (mean 16 months in this group) and was six months or less in 117.
- Source reviewed
- Original indexed abstract. It reports event counts and total strata sizes.
Study limitations
- The clinical finding varied across prior-treatment groups and involved few events. The 1996 biomarker paper reanalyzed these same 352 participants. The trial predates modern combination antiretroviral treatment.
Reviewed 2026-11-14.
Observational study · 2025
Thymopentin and infections in a peritoneal dialysis cohort
Infection episodes · 36 versus 49, or 0.73 versus 1.00 episodes per person-year. Adjusted hazard ratio for first infection 0.54 (95% CI 0.30–0.95, p=0.034).
Study notes and original source
Thymopentin and infections in a peritoneal dialysis cohort
Defined pentapeptide (RKDVY)
X. Chen, Y. Ruan, J. Xie, X. Huang, C. Zhang, Y. Cui, T. Xu, H. Ren · BMC Nephrology 26, article 538
Infection episodes · 36 versus 49, or 0.73 versus 1.00 episodes per person-year. Adjusted hazard ratio for first infection 0.54 (95% CI 0.30–0.95, p=0.034).
Results and tables
Reported findings and study design
Reported findings
Retrospective cohort with 48 weeks of follow-up. The thymopentin protocol was 10 mg subcutaneously on each of the first five days, then three times weekly for 23 weeks.
Population or model 100 peritoneal dialysis patients from a single center, 50 treated with thymopentin and 50 controls.
Dose, route and schedule
Retrospective cohort with 48 weeks of follow-up. The thymopentin protocol was 10 mg subcutaneously on each of the first five days, then three times weekly for 23 weeks.
Protocol source ↗ · Original full text, including the infection and safety tables.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Infection episodes | 36 versus 49, or 0.73 versus 1.00 episodes per person-year. Adjusted hazard ratio for first infection 0.54 (95% CI 0.30–0.95, p=0.034). | |
| Peritonitis episodes | 1 versus 8 (p=0.031). | |
| Severe infection and mortality | 5 versus 10 severe infections (p=0.161). One patient died in each group. | |
| IL-6 at week 12 | The full results show a smaller median increase (0.20 versus 1.10 pg/mL, p=0.036). There was no significant difference at weeks 24 or 48. | |
| Cell counts and adverse-event reporting | No significant differences in CD4 counts or the CD4:CD8 ratio. The authors reported 12 versus 24 adverse events. |
Reported events during 48 weeks
| Measure | Thymopentin (n=50) | Control (n=50) |
|---|---|---|
| Infection episodes | 36 | 49 |
| Infection episodes per person-year | 0.73 | 1.00 |
| Peritonitis episodes | 1 | 8 |
| Severe infection | 5 | 10 |
| Deaths | 1 | 1 |
| Reported adverse events | 12 | 24 |
Treatment was selected in routine care. Differences in patients or care may have influenced the association. The study was small for severe infection and mortality. The article reports partial funding from the thymopentin manufacturer.
Source for these results ↗ · Reviewed 2026-11-14
- Population / setting
- 100 peritoneal dialysis patients from a single center, 50 treated with thymopentin and 50 controls.
- Source reviewed
- Original full text, including the infection and safety tables.
Study limitations
- Treatment was selected in routine care. Differences in patients or care may have influenced the association. The study was small for severe infection and mortality. The article reports partial funding from the thymopentin manufacturer.
Reviewed 2026-11-14.
Randomized study in people · 2024
Thymopentin added to inhaled triple therapy in stable COPD
Study-defined overall response · 94.67% with thymopentin plus inhaled therapy versus 82.67% with inhaled therapy alone (p<0.05).
Study notes and original source
Thymopentin added to inhaled triple therapy in stable COPD
Defined pentapeptide (RKDVY)
Wei Chen, Bayinsang, Xuelin Jiang, Xulin Huang, Shuai Shi · Drugs & Clinic 39(12), 3125–3129
Study-defined overall response · 94.67% with thymopentin plus inhaled therapy versus 82.67% with inhaled therapy alone (p<0.05).
Results and tables
Reported findings and study design
Reported findings
The authors report random assignment. Both groups used inhaled budesonide, glycopyrronium and formoterol (two inhalations twice a day). The intervention group also received thymopentin 10 mg subcutaneously twice weekly for three months.
Population or model 150 patients with stable chronic obstructive pulmonary disease, 75 per group.
Dose, route and schedule
The authors report random assignment. Both groups used inhaled budesonide, glycopyrronium and formoterol (two inhalations twice a day). The intervention group also received thymopentin 10 mg subcutaneously twice weekly for three months.
Protocol source ↗ · Publisher’s original Chinese abstract and bilingual metadata.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Study-defined overall response | 94.67% with thymopentin plus inhaled therapy versus 82.67% with inhaled therapy alone (p<0.05). | |
| Lung function and subsequent events | The abstract reports better spirometry and fewer exacerbations and readmissions with adjunctive thymopentin. It omits the group-level values for these outcomes. |
The abstract gives no details on allocation concealment or masking. The overall response measure is specific to this study. The Chinese methods identify the comparator as inhaled triple therapy.
Source for these results ↗ · Reviewed 2026-11-14
- Population / setting
- 150 patients with stable chronic obstructive pulmonary disease, 75 per group.
- Source reviewed
- Publisher’s original Chinese abstract and bilingual metadata.
Study limitations
- The abstract gives no details on allocation concealment or masking. The overall response measure is specific to this study. The Chinese methods identify the comparator as inhaled triple therapy.
Reviewed 2026-11-14.
Animal research · 1979
Identification of the thymopoietin 32–36 pentapeptide
Immune-cell assays · The peptide promoted mouse T-cell precursor differentiation, inhibited B-lineage precursor differentiation in culture and reduced splenic autologous rosette-forming cells in athymic mice.
Study notes and original source
Identification of the thymopoietin 32–36 pentapeptide
Defined pentapeptide (RKDVY)
G. Goldstein, M. P. Scheid, E. A. Boyse, D. H. Schlesinger, J. Van Wauwe · Science 204(4399), 1309–1310
Immune-cell assays · The peptide promoted mouse T-cell precursor differentiation, inhibited B-lineage precursor differentiation in culture and reduced splenic autologous rosette-forming cells in athymic mice.
Results and tables
Reported findings and study design
Findings described in words
The investigators synthesized thymopoietin residues 32–36, Arg–Lys–Asp–Val–Tyr, and tested the fragment in mouse immune-cell differentiation and rosette-formation assays.
Population or model Cultured mouse lymphoid precursors and athymic mice.
Dose, route and schedule
The investigators synthesized thymopoietin residues 32–36, Arg–Lys–Asp–Val–Tyr, and tested the fragment in mouse immune-cell differentiation and rosette-formation assays.
Protocol source ↗ · Original indexed abstract.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Immune-cell assays | The peptide promoted mouse T-cell precursor differentiation, inhibited B-lineage precursor differentiation in culture and reduced splenic autologous rosette-forming cells in athymic mice. |
These experiments concern mouse immune-cell responses. The abstract does not give numerical effect sizes or group sizes.
Source for these results ↗ · Reviewed 2026-11-14
- Population / setting
- Cultured mouse lymphoid precursors and athymic mice.
- Source reviewed
- Original indexed abstract.
Study limitations
- These experiments concern mouse immune-cell responses. The abstract does not give numerical effect sizes or group sizes.
Reviewed 2026-11-14.
Lab research · 1979
Thymopentin stability in isolated human plasma
Apparent half-life in plasma · Approximately 30 seconds in isolated plasma. The investigators observed no comparable degradation in the saline control.
Study notes and original source
Thymopentin stability in isolated human plasma
Defined pentapeptide (RKDVY)
J. P. Tischio, J. E. Patrick, H. S. Weintraub, M. Chasin, G. Goldstein · International Journal of Peptide and Protein Research 14(5), 479–484
Apparent half-life in plasma · Approximately 30 seconds in isolated plasma. The investigators observed no comparable degradation in the saline control.
Results and tables
Reported findings and study design
Reported findings
Tritiated thymopentin was incubated in plasma and saline. Thin-layer chromatography and radiolabel measurements tracked the parent peptide and four tyrosine-containing breakdown products.
Population or model Isolated human plasma and a saline control.
Dose, route and schedule
Tritiated thymopentin was incubated in plasma and saline. Thin-layer chromatography and radiolabel measurements tracked the parent peptide and four tyrosine-containing breakdown products.
Protocol source ↗ · Original indexed abstract.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Apparent half-life in plasma | Approximately 30 seconds in isolated plasma. The investigators observed no comparable degradation in the saline control. |
This laboratory assay did not measure half-life after administration to people.
Source for these results ↗ · Reviewed 2026-11-14
- Population / setting
- Isolated human plasma and a saline control.
- Source reviewed
- Original indexed abstract.
Study limitations
- This laboratory assay did not measure half-life after administration to people.
Reviewed 2026-11-14.
Animal research · 2025
Thymopentin reduced tumor volume in immunocompetent mouse models
Hepa1-6 tumor volume at day 24 · 341.10 ± 61.97 mm³ with thymopentin versus 666.01 ± 88.62 mm³ with saline (mean ± SEM, p<0.001). The treated mean was 48.8% lower.
Study notes and original source
Thymopentin reduced tumor volume in immunocompetent mouse models
· Original journal article
M. A. Hossain, Y. Zhang, L. Ji, Y. Chen, Y. Luan, Y. Si, Y. Fang, J. Qiu, Z. Wang, G. Liu · Biomedicines 13(10), 2494.
Hepa1-6 tumor volume at day 24 · 341.10 ± 61.97 mm³ with thymopentin versus 666.01 ± 88.62 mm³ with saline (mean ± SEM, p<0.001). The treated mean was 48.8% lower.
Results and tables
Reported findings and study design
Reported findings
Thymopentin 20 mg/kg subcutaneously daily versus saline. Hepa1-6 treatment began on day 6 after inoculation and continued through day 24. Melanoma pretreatment began two weeks before inoculation and continued two weeks afterward. The athymic LM3 comparison also included sorafenib 30 mg/kg daily.
Population or model Hepa1-6 liver tumor comparison used 11 mice per arm pooled from two experiments. The melanoma pretreatment comparison and athymic LM3 comparison used five mice per arm.
Dose, route and schedule
Thymopentin 20 mg/kg subcutaneously daily versus saline. Hepa1-6 treatment began on day 6 after inoculation and continued through day 24. Melanoma pretreatment began two weeks before inoculation and continued two weeks afterward. The athymic LM3 comparison also included sorafenib 30 mg/kg daily.
Protocol source ↗ · Original full text, figures and reported group means.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Hepa1-6 tumor volume at day 24 | 341.10 ± 61.97 mm³ with thymopentin versus 666.01 ± 88.62 mm³ with saline (mean ± SEM, p<0.001). The treated mean was 48.8% lower. | |
| B16-F10 melanoma tumor volume at day 14 | 461.36 ± 93.85 mm³ versus 1,155.11 ± 232.42 mm³ (mean ± SEM, p<0.01) in the pretreatment model. | |
| Athymic LM3 model and cell assays | Thymopentin failed to suppress tumor growth in the athymic model, and direct treatment did not reduce Hepa1-6 cell viability in vitro. Sorafenib inhibited growth in the athymic comparison. | |
| Adoptive T-cell transfer in melanoma-bearing mice | 170.54 ± 30.81 mm³ with thymopentin plus OT-1 cells versus 368.64 ± 130.24 mm³ with OT-1 cells alone (p<0.05, five mice per group). | |
| Immune readouts | The authors reported increased thymus mass and thymic T-cell counts and fewer PD-1/TIM-3 double-positive T cells in the tumor model. |
The liver tumor comparisons used different cell lines in immunocompetent and athymic mice. The results support an immune mechanism in the tested models and leave clinical efficacy and durability unresolved. The melanoma experiment started before tumor implantation.
Source for these results ↗ · Reviewed 2026-11-14
- Population / setting
- Hepa1-6 liver tumor comparison used 11 mice per arm pooled from two experiments. The melanoma pretreatment comparison and athymic LM3 comparison used five mice per arm.
- Source reviewed
- Original full text, figures and reported group means.
Study limitations
- The liver tumor comparisons used different cell lines in immunocompetent and athymic mice. The results support an immune mechanism in the tested models and leave clinical efficacy and durability unresolved. The melanoma experiment started before tumor implantation.
Reviewed 2026-11-14.
Randomized study in people · 1994
Thymopentin, G-CSF and chemotherapy-associated fever
Chemotherapy-related febrile episodes · 52% with thymopentin versus 64% with placebo. The difference was not statistically significant.
Study notes and original source
Thymopentin, G-CSF and chemotherapy-associated fever
· Original indexed abstract
V. Gebbia, R. Valenza, A. Testa, G. Cannata, N. Borsellino, N. Gebbia · Anticancer Research 14(2B), 731–734.
Chemotherapy-related febrile episodes · 52% with thymopentin versus 64% with placebo. The difference was not statistically significant.
Results and tables
Reported findings and study design
Reported findings
Prospective randomized comparison of thymopentin, subcutaneous G-CSF, both agents, and placebo. Cochrane’s extraction lists thymopentin 50 mg IM every other day starting two days after chemotherapy and continuing until the next cycle.
Population or model 100 patients receiving highly myelosuppressive chemotherapy for advanced carcinoma randomized across four arms.
Dose, route and schedule
Prospective randomized comparison of thymopentin, subcutaneous G-CSF, both agents, and placebo. Cochrane’s extraction lists thymopentin 50 mg IM every other day starting two days after chemotherapy and continuing until the next cycle.
Protocol source ↗ · Original indexed abstract for findings. The dosing detail comes from the Cochrane study description.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Chemotherapy-related febrile episodes | 52% with thymopentin versus 64% with placebo. The difference was not statistically significant. | |
| G-CSF and combination | 22% with G-CSF versus 64% with placebo (p<0.001). Adding thymopentin did not significantly improve the result with G-CSF alone. |
The accessible journal abstract does not supply per-arm denominators or a combination-arm percentage. The study measured supportive-care outcomes during chemotherapy.
Source for these results ↗ · Reviewed 2026-11-14
- Population / setting
- 100 patients receiving highly myelosuppressive chemotherapy for advanced carcinoma randomized across four arms.
- Source reviewed
- Original indexed abstract for findings. The dosing detail comes from the Cochrane study description.
Study limitations
- The accessible journal abstract does not supply per-arm denominators or a combination-arm percentage. The study measured supportive-care outcomes during chemotherapy.
Reviewed 2026-11-14.
Review of earlier studies · 2026
Colorectal cancer review of thymopentin and other thymic preparations
Karnofsky Performance Status · Pooled mean difference +4.35 points (95% CI 1.90–6.80) from two trials, rated very low certainty.
Study notes and original source
Colorectal cancer review of thymopentin and other thymic preparations
· Systematic review
G. Zhang, Y. Zhou, T. Sun, X. Chen, Y. Zheng · Frontiers in Oncology 16, 1957041.
Karnofsky Performance Status · Pooled mean difference +4.35 points (95% CI 1.90–6.80) from two trials, rated very low certainty.
Results and tables
Reported findings and study design
Reported findings
The two relevant comparisons used capecitabine plus oxaliplatin (XELOX), with or without thymopentin 10 mg IM daily for 15 days per course over four courses, as reported in Table 1.
Population or model 30 controlled studies across multiple thymic preparations, 2,514 participant records. Two thymopentin-plus-XELOX reports contributed 130 records to the functional-status estimate, with 40/40 and 25/25 in the respective studies.
Dose, route and schedule
The two relevant comparisons used capecitabine plus oxaliplatin (XELOX), with or without thymopentin 10 mg IM daily for 15 days per course over four courses, as reported in Table 1.
Protocol source ↗ · Published review, Tables 1–3 and Figures 6–7. The two thymopentin reports are represented here by the review’s extraction.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Karnofsky Performance Status | Pooled mean difference +4.35 points (95% CI 1.90–6.80) from two trials, rated very low certainty. | |
| Hand–foot syndrome | Pooled RR 0.37 (95% CI 0.17–0.82) from the same two studies, rated low certainty. Neurotoxicity, granulocytopenia and gastrointestinal reactions were inconclusive. | |
| One-year survival | One 80-person trial contributed RR 1.52 (95% CI 1.18–1.95), rated very low certainty. There was no pool of independent survival estimates. |
The review flagged identical arm-level standard deviations across the two performance-status reports and could not confirm their full independence. These are review totals across several preparations and are not additional patients. The review concluded that the evidence was insufficient for routine clinical use.
Source for these results ↗ · Reviewed 2026-11-14
- Population / setting
- 30 controlled studies across multiple thymic preparations, 2,514 participant records. Two thymopentin-plus-XELOX reports contributed 130 records to the functional-status estimate, with 40/40 and 25/25 in the respective studies.
- Source reviewed
- Published review, Tables 1–3 and Figures 6–7. The two thymopentin reports are represented here by the review’s extraction.
Study limitations
- The review flagged identical arm-level standard deviations across the two performance-status reports and could not confirm their full independence. These are review totals across several preparations and are not additional patients. The review concluded that the evidence was insufficient for routine clinical use.
Reviewed 2026-11-14.
Experiment described in a patent · 1980
Thymopoietin pentapeptide and its synthesis — US4190646A
The original patent reports differentiation of T-cell precursors in a cell assay.
Cell differentiation assay · The grant reports induction of Thy-1-positive T cells in a 1 ng/mL to 10 µg/mL concentration range for the disclosed peptide class. The synthetic peptides did not induce complement-receptor-positive B-cell differentiation.
Study notes and original source
Thymopoietin pentapeptide and its synthesis — US4190646A
Patent-defined substance or composition · Patent publication
Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Gideon Goldstein, David H. Schlesinger · US4190646A · patent family 26676220
The original patent reports differentiation of T-cell precursors in a cell assay.
Results and tables
Reported patent results
Findings described in words
The original patent reports differentiation of T-cell precursors in a cell assay.
Solid-phase synthesis of peptides bearing the RKDVY sequence, followed by in vitro lymphocyte differentiation assays.
Population or model Solid-phase synthesis of peptides bearing the RKDVY sequence, followed by in vitro lymphocyte differentiation assays.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Cell differentiation assay | The grant reports induction of Thy-1-positive T cells in a 1 ng/mL to 10 µg/mL concentration range for the disclosed peptide class. The synthetic peptides did not induce complement-receptor-positive B-cell differentiation. |
The reported concentration range describes laboratory activity across the disclosed peptides. The filing provides no patient outcome data.
Source for these results ↗ · Reviewed 2026-11-14
- Population / setting
- Solid-phase synthesis of peptides bearing the RKDVY sequence, followed by in vitro lymphocyte differentiation assays.
- Source reviewed
- Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Study limitations
- The cell assays describe the same early research program as the 1979 Science paper. They do not establish a separate clinical cohort.
- The reported concentration range describes laboratory activity across the disclosed peptides. The filing provides no patient outcome data.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Reviewed 2026-11-14.
Experiment described in a patent · 1987
Thymopentin for allergy symptoms — EP0235904A2
In the patent’s ragweed-allergy example, the mean weekly symptom count was 9.20 with IV thymopentin versus 19.22 with placebo. The subcutaneous comparison was statistically inconclusive.
Mean weekly symptom count, IV arm · 9.20 versus 19.22 with placebo (p=0.0145).
Study notes and original source
Thymopentin for allergy symptoms — EP0235904A2
Patent-defined substance or composition · Patent publication
Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Gideon Goldstein · EP0235904A2 · patent family 25236742
In the patent’s ragweed-allergy example, the mean weekly symptom count was 9.20 with IV thymopentin versus 19.22 with placebo. The subcutaneous comparison was statistically inconclusive.
Results and tables
Reported patent results
Reported findings
In the patent’s ragweed-allergy example, the mean weekly symptom count was 9.20 with IV thymopentin versus 19.22 with placebo. The subcutaneous comparison was statistically inconclusive.
30 participants randomized, 10 per arm, in a double-blind, double-dummy comparison. Thymopentin 50 mg subcutaneously three times weekly, thymopentin 100 mg intravenously once weekly, or matching placebo injections for 12 weeks. Table I uses ten weeks of symptom diaries.
Population or model 30 participants randomized, 10 per arm, in a double-blind, double-dummy comparison. Thymopentin 50 mg subcutaneously three times weekly, thymopentin 100 mg intravenously once weekly, or matching placebo injections for 12 weeks. Table I uses ten weeks of symptom diaries.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Mean weekly symptom count, IV arm | 9.20 versus 19.22 with placebo (p=0.0145). | |
| Mean weekly symptom count, subcutaneous arm | 12.84 versus 19.22 with placebo (p=0.1394). |
Average weekly symptom counts from Table I
| Group (10 assigned each) | Mild | Severe | Total | Total p vs placebo |
|---|---|---|---|---|
| 50 mg subcutaneous | 10.20 | 2.64 | 12.84 | 0.1394 |
| 100 mg intravenous | 7.43 | 1.77 | 9.20 | 0.0145 |
| Placebo | 13.90 | 5.32 | 19.22 | — |
The small patent example uses self-reported symptoms and multiple comparisons. It gives no numerical adverse-event results for this example.
Source for these results ↗ · Reviewed 2026-11-14
- Population / setting
- 30 participants randomized, 10 per arm, in a double-blind, double-dummy comparison. Thymopentin 50 mg subcutaneously three times weekly, thymopentin 100 mg intravenously once weekly, or matching placebo injections for 12 weeks. Table I uses ten weeks of symptom diaries.
- Source reviewed
- Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Study limitations
- The European and US texts describe the same 30-person trial. A 1986 conference abstract is cited in the family and may describe the same cohort.
- The small patent example uses self-reported symptoms and multiple comparisons. It gives no numerical adverse-event results for this example.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Reviewed 2026-11-14.
Research collection curated by @PepMariner · editorial standards. Send a source correction ↗
Browse bibliography & PDFs ↗